Lantheus Sharpens Focus on Radiodiagnostics, Pursues Radiotherapeutic Divestitures
Event summary
- Lantheus reported $406.8M in Q4 2025 revenue, up 4% YoY, with full-year revenue at $1.54B.
- PYLARIFY sales declined 9.7% YoY in Q4, while Neuraceq sales reached $31M.
- Company repurchased $100M of shares in Q4 2025 under a stock repurchase plan approved in July 2025.
- Lantheus divested its legacy SPECT business to SHINE Technologies LLC effective January 1, 2026.
- Full-year 2026 revenue guidance set at $1.4B–$1.45B, with adjusted EPS guidance of $5.00–$5.25.
The big picture
Lantheus is refocusing its portfolio on PET radiodiagnostics, a strategic shift aimed at capitalizing on the growing demand for advanced imaging technologies in oncology and neurology. The divestiture of its SPECT business and the pursuit of value-maximizing alternatives for radiotherapeutic assets signal a broader industry trend toward specialization and operational efficiency. With up to four FDA approvals expected in 2026, the company's ability to execute on its strategic priorities will be a key determinant of its long-term success.
What we're watching
- Regulatory Approvals
- The pace at which Lantheus secures FDA approvals for its three radiodiagnostic assets in 2026 will determine its ability to execute on its strategic focus.
- Market Differentiation
- Whether Lantheus can clinically and commercially differentiate its products in a competitive radiopharmaceutical market will impact its long-term growth prospects.
- Capital Allocation
- How Lantheus allocates capital to support sustainable growth and maximize value from its radiotherapeutic assets will be critical to its strategic success.
Related topics